Form 8-K - Current report:
SEC Accession No. 0001193125-25-154016
Filing Date
2025-07-01
Accepted
2025-07-01 16:15:28
Documents
15
Period of Report
2025-07-01
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d917926d8k.htm   iXBRL 8-K 38447
2 EX-99.1 d917926dex991.htm EX-99.1 21592
6 GRAPHIC g917926g0701213458385.jpg GRAPHIC 2618
7 GRAPHIC g917926g0701213849473.jpg GRAPHIC 2618
  Complete submission text file 0001193125-25-154016.txt   201664

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ikna-20250701.xsd EX-101.SCH 2868
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikna-20250701_lab.xml EX-101.LAB 19500
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikna-20250701_pre.xml EX-101.PRE 12168
17 EXTRACTED XBRL INSTANCE DOCUMENT d917926d8k_htm.xml XML 3908
Mailing Address 50 NORTHERN AVE. BOSTON MA 02210
Business Address 50 NORTHERN AVE. BOSTON MA 02210 857-343-8292
Ikena Oncology, Inc. (Filer) CIK: 0001835579 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40287 | Film No.: 251096530
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)